Interleukin-12: Clinical usage and molecular markers of cancer susceptibility

References

• Abbas AK, Lichtman AH, Pillai S. 2011. Cellular and molecular immunology. Philadelphia, PA: Elsevier.
   Google Scholar
• Acquaviva J, Chen X, Ren R. 2008. IRF-4 functions as a tumor suppressor in early B-cell development. Blood. 112 9: 3798–3806.
   Google Scholar
• Alatrash G, Hutson TE, Molto L, Richmond A, Nemec C, Mekhail T, Elson P, Tannenbaum C, Olencki T, Finke J, Bukowski RM. 2004. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: Phase I trial of patients with metastatic renal cell carcinoma ormalignant melanoma. J Clin Oncol. 22:2891–2900.
   PubMed Web of Science ®Google Scholar
• Aldred MA, Eng C. 2006. SNP'ing at nasopharyngeal cancer susceptibility: For whom the bell TOLLs. Cancer Biol Ther. 5:1292–1293.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Witzig TE, Kurtin PJ, Sloan JA, Jelinek DF, Howell KG, Markovic SN, Habermann TM, Klee GG, Atherton PJ, Erlichman C. 2002. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. Blood. 99 1: 67–74.
   PubMed Web of Science ®Google Scholar
• Asadullah K, Sterry W, Volk HD. 2003. Interleukin-10 therapy—review of a new approach. Pharmacol Rev. 55 2: 241–269.
   PubMed Web of Science ®Google Scholar
• Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, Mier JW, Canning CM, Battiato L, Tahara H, Sherman ML. 1997. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res. 3 3: 409–417.
   PubMed Web of Science ®Google Scholar
• Bajetta E, Del Vecchio M, Mortarini R, Nadeau R, Rakhit A, Rimassa L, Fowst C, Borri A, Anichini A, Parmiani G. 1998. Pilot study of subcutaneous recombinant human interleukin 12 in metastatic melanoma. Clin Cancer Res. 4 1: 75–85.
   PubMed Web of Science ®Google Scholar
• Becskei A, Grusby MJ. 2007. Contribution of IL-12R mediated feedback loop to Th1 cell differentiation. FEBS Lett. 581 27: 5199–5206.
   Google Scholar
• Ben Chaaben A, Busson M, Douik H, Boukouaci W, Mamoghli T, Chaouch L, Harzallah L, Dorra S, Fortier C, Ghanem A, Charron D, Krishnamoorthy R, Guemira F, Tamouza R. 2011. Association of IL-12p40+1188 A/C polymorphism with nasopharyngeal cancer risk and tumor extension. Tissue Antigens. 78 2: 148–151.
   PubMedGoogle Scholar
• Berger FG. 2004. The interleukin-6 gene: A susceptibility factor that may contribute to racial and ethnic disparities in breast cancer mortality. Breast Cancer Res Treat. 88 3: 281–285.
   Google Scholar
• Beyer M, Schultze JL. 2006. Regulatory T cells in cancer. Blood. 108:804–811.
   PubMed Web of Science ®Google Scholar
• Boggio K, Di Carlo E, Rovero S, Cavallo F, Quaglino E, Lollini PL, Nanni P, Nicoletti G, Wolf S, Musiani P, Forni G. 2000. Ability of systemic interleukin-12 to hamper progressive stages of mammary carcinogenesis in HER2/neu transgenic mice. Cancer Res. 60 2: 359–364.
   PubMed Web of Science ®Google Scholar
• Bondy GS, Pestka JJ. 2000. Immunomodulation by fungal toxins. J Toxicol Environ Health B Crit Rev. 3:109–143.
   PubMed Web of Science ®Google Scholar
• Bouker KB, Skaar TC, Riggins RB, Harburger DS, Fernandez DR, Zwart A, Wang A, Clarke R. 2005. Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis. Carcinogenesis. 26 9: 1527–1535.
   PubMed Web of Science ®Google Scholar
• Bowie ML, Ibarra C, Seewalt VL. 2008. IRF-1 promotes apoptosis in p53-damaged basal-type human mammary epithelial cells: A model for early basal-type mammary carcinogenesis. Adv Exp Med Biol. 617:367–374.
   Google Scholar
• Bree AG, Schlerman FJ, Kaviani MD, Hastings RC, Hitz SL, Goldman SJ. 1994. Multiple effects on peripheral hematology following administration of recombinant human interleukin 12 to nonhuman primates. Biochem Biophys Res Commun. 204 3: 1150–1157.
   Google Scholar
• Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK. 1993. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 178 4: 1223–1230.
   PubMed Web of Science ®Google Scholar
• Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, Barnes R, Watson P, Allen-Vercoe E, Moore RA, Holt RA. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res. 2012 22(2): 299–306.
   Google Scholar
• Cavallo F, Quaglino E, Cifaldi L, Di Carlo E, André A, Bernabei P, Musiani P, Forni G, Calogero RA. 2001. Interleukin 12-activated lymphocytes influence tumor genetic programs. Cancer Res. 61 8: 3518–3523.
   PubMed Web of Science ®Google Scholar
• Cavanaugh VJ, Guidotti LG, Chisari FV. 1997. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J Virol. 71 4: 3236–3243.
   PubMed Web of Science ®Google Scholar
• Cerhan JR, Wang S, Maurer MJ, Ansell SM, Geyer SM, Cozen W, Morton LM, Davis S, Severson RK, Rothman N, Lynch CF, Wacholder S, Chanock SJ, Habermann TM, Hartge P. 2007. Prognostic significance of host immune gene polymorphisms in follicular lymphoma survival. Blood. 109 12: 5439–5446.
   Google Scholar
• Chatterjee N, Hartge P, Cerhan JR, Cozen W, Davis S, Ishibe N, Colt J, Goldin L, Severson RK. 2004. Risk of non-Hodgkin lymphoma and family history of lymphatic, hematologic, and other cancers. Cancer Epidemiol Biomarkers Prev. 13:1415–1421.
   PubMed Web of Science ®Google Scholar
• Chen X, Han S, Wang S, Zhou X, Zhang M, Dong J, Shi X, Qian N, Wang X, Wei Q, Shen H, Hu Z. 2009. Interactions of IL-12A and IL-12B polymorphisms on the risk of cervical cancer in Chinese women. Clin Cancer Res. 15 1: 400–405.
   PubMed Web of Science ®Google Scholar
• Davoodi-Semiromi A, Yang JJ, She JX. 2002. IL-12p40 is associated with type 1 diabetes in Caucasian-American families. Diabetes. 51 7: 2334–2336.
   Google Scholar
• Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A. 2007. Interleukin-12: Biological properties and clinical application. Clin Cancer Res. 13 16: 4677–4685.
   PubMed Web of Science ®Google Scholar
• Delgado M, Ganea D. 1999. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit interleukin-12 transcription by regulating nuclear factor kappaB and Ets activation. J Biol Chem. 274 45: 31930–31940.
   Google Scholar
• Dien Bard J, Gelebart P, Anand M, Zak Z, Hegazy SA, Amin HM, Lai R. 2009. IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma. Am J Pathol. 175 2: 825–834.
   Google Scholar
• Ekbom A, Helmick C, Zack M, Adami HO. 1990. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet. 336 8711: 357–359.
   PubMed Web of Science ®Google Scholar
• Fan H, Walters CS, Dunston GM, Tackey R. 2002. IL-12 plays a significant role in the apoptosis of human T cells in the absence of antigenic stimulation. Cytokine. 19:126–137.
   Google Scholar
• Filer C, Ho P, Smith RL, Griffiths C, Young HS, Worthington J, Bruce IN, Barton A. 2008. Investigation of association of the IL12B and IL23R genes with psoriatic arthritis. Arthritis Rheum. 58 12: 3705–3709.
   PubMedGoogle Scholar
• Fisher SG, Fisher RI. 2004. The epidemiology of non-Hodgkin's lymphoma. Oncogene. 23 38: 6524–6534.
   PubMed Web of Science ®Google Scholar
• Foukas LC, Panayotou G, Shepherd PR. 2004. Direct interaction of major histocompatibility complex class II-derived peptides with class Ia phosphoinositide 3-kinase results in dose-dependent stimulatory effects. J Biol Chem. 279 9: 7505–7511.
   Google Scholar
• Friedmann E, Hauben E, Maylandt K, Schleeger S, Vreugde S, Lichtenthaler SF, Kuhn PH, Stauffer D, Rovelli G, Martoglio B. 2006. SPPL2a and SPPL2b promote intramembrane proteolysis of TNFalpha in activated dendritic cells to trigger IL-12 production. Nat Cell Biol. 8 8: 843–848.
   PubMed Web of Science ®Google Scholar
• Gately MK, Renzetti LM, Magram J, Stern AS, Adorini L, Gubler U, Presky DH. 1998. The interleukin-12/interleukin-12-receptor system: Role in normal and pathologic immune responses. Annu Rev Immunol. 16:495–521.
   PubMed Web of Science ®Google Scholar
• Goldstein D, Laszlo J. 1988. The role of interferon in cancer therapy: A current perspective. CA Cancer J Clin. 38 5: 258–277.
   PubMed Web of Science ®Google Scholar
• Gollob JA, Veenstra KG, Parker RA, Mier JW, McDermott DF, Clancy D, Tutin L, Koon H, Atkins MB. 2003. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. J Clin Oncol. 21 13: 2564–2573.
   PubMed Web of Science ®Google Scholar
• Gravisaco MJ, Mongini C, Alvarez E, Ruybal P, Escalada A, Sanchez-Lockhart M, Hajos S, Waldner C. 2003. IL-2, IL-10, IL-15 and TNF are key regulators of murine T-cell lymphoma growth. Int J Mol Med. 12 4: 627–632.
   Google Scholar
• Guidotti LG, Guilhot S, Chisari FV. 1994. Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and -independent pathways. J Virol. 68 3: 1265–1270.
   PubMed Web of Science ®Google Scholar
• Guo Q, Shen S, Li X, Tang K, Zhou W. 2011. Inflammatory factors promote the development of colorectal cancer. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 36 7: 646–649.
   Google Scholar
• Han SS, Cho EY, Lee TS, Kim JW, Park NH, Song YS, Kim JG, Lee HP, Kang SB. 2008. Interleukin-12 p40 gene (IL12B) polymorphisms and the risk of cervical cancer in Korean women. Eur J Obstet Gynecol Reprod Biol. 140 1: 71–75.
   PubMed Web of Science ®Google Scholar
• Hashmi MH, Van Veldhuizen PJ. 2010. Interleukin-21: Updated review of phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma. Expert Opin Biol Ther. 10 5: 807–817.
   PubMed Web of Science ®Google Scholar
• Hess SD, Egilmez NK, Bailey N, Anderson TM, Mathiowitz E, Bernstein SH, Bankert RB. 2003. Human CD4+T cells present within the microenvironment of human lung tumors are mobilized by the local and sustained release of IL-12 to kill tumors in situ by indirect effects of IFN-gamma. J Immunol. 170 1: 400–412.
   PubMed Web of Science ®Google Scholar
• Hill HC, Conway TFJr, Sabel MS, Jong YS, Mathiowitz E, Bankert RB, Egilmez NK. 2002. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: Coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. Cancer Res. 62 24: 7254–7263.
   PubMed Web of Science ®Google Scholar
• Hou L, El-Omar EM, Chen J, Grillo P, Rabkin CS, Baccarelli A, Yeager M, Chanock SJ, Zatonski W, Sobin LH, Lissowska J, Fraumeni JFJr, Chow WH. 2007. Polymorphisms in Th1-type cell-mediated response genes and risk of gastric cancer. Carcinogenesis. 28 1: 118–123.
   PubMed Web of Science ®Google Scholar
• Howell WM, Rose-Zerilli MJ. 2007. Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J Nutr. 137 1 Suppl: 194S–199S.
   Google Scholar
• Howell WM, Turner SJ, Theaker JM, Bateman AC. 2003. Cytokine gene single nucleotide polymorphisms and susceptibility to and prognosis in cutaneous malignant melanoma. Eur J Immunogenet. 30 6: 409–414.
   PubMedGoogle Scholar
• Huang ZQ, Wang JL, Pan GG, Wei YS. 2011. Association of single nucleotide polymorphisms in IL-12 and IL-27 genes with colorectal cancer risk. Clin Biochem. 45 1–2: 54–59.
   Google Scholar
• Ikeda H, Old LJ, Schreiber RD. 2002. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev.. 13 2: 95–109.
   PubMed Web of Science ®Google Scholar
• Jakobisiak M, Golab J, Lasek W. 2011. Interleukin 15 as a promising candidate for tumor immunotherapy. Cytokine Growth Factor Rev. 22 2: 99–108.
   Web of Science ®Google Scholar
• Jones EA, Pringle JH, Angel CA, Rees RC. 2002. Th1/Th2 cytokine expression and its relationship with tumor growth in B cell non-Hodgkin's lymphoma (NHL). Leuk Lymphoma. 43 6: 1313–1321.
   PubMed Web of Science ®Google Scholar
• Kadish AS, Timmins P, Wang Y, Ho GY, Burk RD, Ketz J, He W, Romney SL, Johnson A, Angeletti R, Abadi M. 2002. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Albert Einstein Cervix Dysplasia Clinical Consortium. Cancer Epidemiol Biomarkers Prev. 11 5: 483–488.
   PubMed Web of Science ®Google Scholar
• Kanegane C, Sgadari C, Kanegane H, Teruya-Feldstein J, Yao L, Gupta G, Farber JM, Liao F, Liu L, Tosato G. 1998. Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12. J Leukoc Biol. 64 3: 384–392.
   Google Scholar
• Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B, Trinchieri G. 1989. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med. 170 3: 827–845.
   PubMed Web of Science ®Google Scholar
• Kordi Tamandani DM, Shekari M, Suri V. Interleukin-12 gene polymorphism and cervical cancer Risk. Am J Clin Oncol. 2009 (Epub ahead of print).
   Google Scholar
• Kornbluth A, Sachar DB. 2004. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 99 7: 1371–1385.
   PubMed Web of Science ®Google Scholar
• Kurzrock R. 1997. Cytokine deregulation in hematological malignancies: Clinical and biological implications. Clin Cancer Res. 3 12 Pt 2: 2581–2584.
   PubMed Web of Science ®Google Scholar
• Kuwajima S, Sato T, Ishida K, Tada H, Tezuka H, Ohteki T. 2006. Interleukin 15-dependent crosstalk between conventional and plasmacytoid dendritic cells is essential for CpG-induced immune activation. Nat Immunol. 7 7: 740–746.
   PubMedGoogle Scholar
• Landi S, Gemignani F, Bottari F, Gioia-Patricola L, Guino E, Cambray M, Biondo S, Capella G, Boldrini L, Canzian F, Moreno V. 2006. Polymorphisms within inflammatory genes and colorectal cancer. J Negat Results Biomed. 5:15.
   PubMedGoogle Scholar
• Lan Q, Zheng T, Rothman N, Zhang Y, Wang SS, Shen M, Berndt SI, Zahm SH, Holford TR, Leaderer B, Yeager M, Welch R, Boyle P, Zhang B, Zou K, Zhu Y, Chanock S. 2006. Cytokine polymorphisms in the Th1/Th2 pathway and susceptibility to non-Hodgkin lymphoma. Blood. 107 10: 4101–4108.
   Google Scholar
• Lee KM, Shen M, Chapman RS, Yeager M, Welch R, He X, Zheng T, Hosgood HD, Yang D, Berndt SI, Chanock S, Lan Q. 2007. Polymorphisms in immunoregulatory genes, smoky coal exposure and lung cancer risk in Xuan Wei, China. Carcinogenesis. 28 7: 1437–1441.
   PubMed Web of Science ®Google Scholar
• Lehtonen A, Lund R, Lahesmaa R, Julkunen I, Sareneva T, Matikainen S. 2003. IFN-alpha and IL-12 activate IFN regulatory factor 1 (IRF-1), IRF-4, and IRF-8 gene expression in human NK and T cells. Cytokine. 24 3: 81–90.
   Google Scholar
• Lenzi R, Rosenblum M, Verschraegen C, Kudelka AP, Kavanagh JJ, Hicks ME, Lang EA, Nash MA, Levy LB, Garcia ME, Platsoucas CD, Abbruzzese JL, Freedman RS. 2002. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Mullerian carcinoma, gastrointestinal primary malignancies, and mesothelioma. Clin Cancer Res. 8:3686–3695.
   PubMed Web of Science ®Google Scholar
• Liu L, Xu Y, Liu Z, Chen J, Zhang Y, Zhu J, Liu J, Liu S, Ji G, Shi H, Shen H, Hu Z. 2011. IL12 polymorphisms, HBV infection and risk of hepatocellular carcinoma in a high-risk Chinese population. Int J Cancer. 128 7: 1692–1696.
   Google Scholar
• Lowy DR, Schiller JT. 2006. Prophylactic human papillomavirus vaccines. J Clin Invest. 116 5: 1167–1173.
   PubMed Web of Science ®Google Scholar
• Ma X, Trinchieri G. 2001. Regulation of interleukin-12 production in antigen-presenting cells. Adv Immunol. 79:55–92.
   PubMed Web of Science ®Google Scholar
• Mackall CL, Fry TJ, Gress RE. 2011. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol. 11 5: 330–342.
   PubMed Web of Science ®Google Scholar
• Meyaard L, Hovenkamp E, Otto SA, Miedema F. 1996. IL-12-induced IL-10 production by human T cells as a negative feedback for IL-12-induced immune responses. J Immunol. 156:2776–2782.
   PubMed Web of Science ®Google Scholar
• Ming J, Jiang G, Zhang Q, Qiu X, Wang E. Interleukin-7 up-regulates cyclin D1 via activator protein-1 to promote proliferation of cell in lung cancer. Cancer Immunol Immunother. 2012 61(1): 79–88.
   Google Scholar
• Miteva L, Stanilov N, Deliysky T, Mintchev N, Stanilova S. 2009. Association of polymorphisms in regulatory regions of interleukin-12p40 gene and cytokine serum level with colorectal cancer. Cancer Invest. 27 9: 924–931.
   PubMed Web of Science ®Google Scholar
• Mitsuhashi M, Liu J, Cao S, Shi X, Ma X. 2004. Regulation of interleukin-12 gene expression and its anti-tumor activities by prostaglandin E2 derived from mammary carcinomas. J Leukoc Biol. 76 2: 322–332.
   Google Scholar
• Morahan G, Huang D, Ymer SI, Cancilla MR, Stephen K, Dabadghao P, Werther G, Tait BD, Harrison LC. 2001. Linkage disequilibrium of a type 1 diabetes susceptibility locus with a regulatory IL12B allele. Nat Genet. 27:218–221.
   PubMed Web of Science ®Google Scholar
• Morahan G, McKinnon E, Berry J, Browning B, Julier C, Pociot F, James I, Type I Diabetes Genetics Consortium. 2009. Evaluation of IL12B as a candidate type I diabetes susceptibility gene using data from the Type I Diabetes Genetics Consortium. Genes Immun. 10 Suppl 1: S64–S68.
   Google Scholar
• Mortarini R, Borri A, Tragni G, Bersani I, Vegetti C, Bajetta E, Pilotti S, Cerundolo V, Anichini A. 2000. Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+T cells in melanoma patients receiving interleukin 12. Cancer Res. 60 13: 3559–3568.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Bukowski RM. 2006. Targeted therapy for metastatic renal cell carcinoma. J Clin Oncol. 24 35: 5601–5608.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Rakhit A, Thompson JA, Nemunaitis J, Murphy BA, Ellerhorst J, Schwartz LH, Berg WJ, Bukowski RM. 2001. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma. J Interferon Cytokine Res. 21 4: 257–263.
   Google Scholar
• Murakami S, Okubo K, Tsuji Y, Sakata H, Hamada S, Hirayama R. 2004. Serum interleukin-12 levels in patients with gastric cancer. Surg Today. 34 12: 1014–1019.
   PubMed Web of Science ®Google Scholar
• Ménoret E, Maïga S, Descamps G, Pellat-Deceunynck C, Fraslon C, Cappellano M, Moreau P, Bataille R, Amiot M. 2008. IL-21 stimulates human myeloma cell growth through an autocrine IGF-1 loop. J Immunol. 181 10: 6837–6842.
   Google Scholar
• Nair RE, Jong YS, Jones SA, Sharma A, Mathiowitz E, Egilmez NK. 2006. IL-12 + GM-CSF microsphere therapy induces eradication of advanced spontaneous tumors in HER-2/neu transgenic mice but fails to achieve long-term cure due to the inability to maintain effector T-cell activity. J Immunother. 29 1: 10–20.
   PubMed Web of Science ®Google Scholar
• Nakahira M, Tomura M, Iwasaki M, Ahn HJ, Bian Y, Hamaoka T, Ohta T, Kurimoto M, Fujiwara H. 2001. An absolute requirement for STAT4 and a role for IFN-gamma as an amplifying factor in IL-12 induction of the functional IL-18 receptor complex. J Immunol. 167 3: 1306–1312.
   Google Scholar
• Nanni P, Nicoletti G, De Giovanni C, Landuzzi L, Di Carlo E, Cavallo F, Pupa SM, Rossi I, Colombo MP, Ricci C, Astolfi A, Musiani P, Forni G, Lollini PL. 2001. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice. J Exp Med. 194:1195–1205.
   PubMed Web of Science ®Google Scholar
• Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ, Johns A. 1994. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol. 153 4: 1697–1706.
   PubMed Web of Science ®Google Scholar
• Navaglia F, Basso D, Zambon CF, Ponzano E, Caenazzo L, Gallo N, Falda A, Belluco C, Fogar P, Greco E, Di Mario F, Rugge M, Plebani M. 2005. Interleukin 12 gene polymorphisms enhance gastric cancer risk in H. pylori infected individuals. J Med Genet. 42:503–510.
   PubMed Web of Science ®Google Scholar
• Nieters A, Yuan JM, Sun CL, Zhang ZQ, Stoehlmacher J, Govindarajan S, Yu MC. 2005. Effect of cytokine genotypes on the hepatitis B virus-hepatocellular carcinoma association. Cancer. 103 4: 740–748.
   PubMed Web of Science ®Google Scholar
• Noguchi Y, Jungbluth A, Richards EC, Old LJ. 1996. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc Natl Acad Sci USA. 93:11798–11801.
   PubMed Web of Science ®Google Scholar
• Ognjanovic S, Yuan JM, Chaptman AK, Fan Y, Yu MC. 2009. Genetic polymorphisms in the cytokine genes and risk of hepatocellular carcinoma in low-risk non-Asians of USA. Carcinogenesis. 30 5: 758–762.
   Google Scholar
• Parihar R, Nadella P, Lewis A, Jensen R, De Hoff C, Dierksheide JE, VanBuskirk AM, Magro CM, Young DC, Shapiro CL, Carson WE3rd.. 2004. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: Analysis of sustained interferon gamma production in a subset of patients. Clin Cancer Res. 10 15: 5027–5037.
   PubMed Web of Science ®Google Scholar
• Park JS, Cheong JY, Kang JK, Cho JH, Yu S, Shin HD, Park BL, Cho SW. 2007. Association of interleukin-12 gene polymorphism with persistence of hepatitis B virus infection and hepatocellular carcinoma. Korean J Gastroenterol. 50 5: 313–318.
   Google Scholar
• Parsonnet J. 1993. Helicobacter pylori and gastric cancer. Gastroenterol Clin North Am. 22:89–104.
   PubMed Web of Science ®Google Scholar
• Pathak S, Ma S, Trinh L, Eudy J, Wagner KU, Joshi SS, Lu R. 2011. IRF4 is a suppressor of c-Myc induced B cell leukemia. PLoS One. 6 7: e22628.
   Google Scholar
• Peterson AC, Harlin H, Gajewski TF. 2003. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma. J Clin Oncol. 21 12: 2342–2348.
   PubMed Web of Science ®Google Scholar
• Portielje JE, Kruit WH, Schuler M, Beck J, Lamers CH, Stoter G, Huber C, de Boer-Dennert M, Rakhit A, Bolhuis RL, Aulitzky WE. 1999. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer. Clin Cancer Res. 5 12: 3983–3989.
   PubMed Web of Science ®Google Scholar
• Purdue MP, Lan Q, Kricker A, Grulich AE, Vajdic CM, Turner J, Whitby D, Chanock S, Rothman N, Armstrong BK. 2007. Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: Findings from the New South Wales non-Hodgkin Lymphoma Study. Carcinogenesis. 28 3: 704–712.
   Google Scholar
• Qu Y, Taylor JL, Bose A, Storkus WJ. 2011. Therapeutic effectiveness of intratumorally delivered dendritic cells engineered to express the pro-inflammatory cytokine, interleukin (IL)-32. Cancer Gene Ther. 18 9: 663–673.
   Google Scholar
• Rook AH, Wood GS, Yoo EK, Elenitsas R, Kao DM, Sherman ML, Witmer WK, Rockwell KA, Shane RB, Lessin SR, Vonderheid EC. 1999. Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood. 94 3: 902–908.
   PubMed Web of Science ®Google Scholar
• Sarmiento UM, Riley JH, Knaack PA, Lipman JM, Becker JM, Gately MK, Chizzonite R, Anderson TD. 1994. Biologic effects of recombinant human interleukin-12 in squirrel monkeys (Sciureus saimiri). Lab Invest. 71 6: 862–873.
   Google Scholar
• Seno H, Satoh K, Tsuji S, Shiratsuchi T, Harada Y, Hamajima N, Sugano K, Kawano S, Chiba T. 2007. Novel interleukin-4 and interleukin-1 receptor antagonist gene variations associated with non-cardia gastric cancer in Japan: Comprehensive analysis of 207 polymorphisms of 11 cytokine genes. J Gastroenterol Hepatol. 22 5: 729–737.
   Google Scholar
• Serefoglou Z, Yapijakis C, Nkenke E, Vairaktaris E. 2008. Genetic association of cytokine DNA polymorphisms with head and neck cancer. Oral Oncol. 44 12: 1093–1099.
   Google Scholar
• Sgadari C, Angiolillo AL, Tosato G. 1996. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood. 87:3877–3882.
   PubMed Web of Science ®Google Scholar
• Sima X, Xu J, Li Q, Luo L, Liu J, You C. 2011. Gene–gene interactions between interleukin-12A and interleukin-12B with the risk of brain tumor. DNA Cell Biol. 31 2: 219–223.
   Google Scholar
• Smith SE, Hoelzinger DB, Dominguez AL, Van Snick J, Lustgarten J. 2011. Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses. Cancer Immunol Immunother. 60 12: 1775–1787.
   PubMed Web of Science ®Google Scholar
• Stern AS, Podlaski FJ, Hulmes JD, Pan YC, Quinn PM, Wolitzky AG, Familletti PC, Stremlo DL, Truitt T, Chizzonite R, Gately MK. 1990. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA. 87 17: 6808–12.
   Google Scholar
• Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. 1994. Macrophages and angiogenesis. J Leukoc Biol. 55 3: 410–422.
   PubMed Web of Science ®Google Scholar
• Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, Sasaki S, Imai K, Shibue T, Honda K, Taniguchi T. 2003. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature. 424 6948: 516–523.
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Millward M, Mainwaring P, Kefford R, Logan T, Pavlick A, Kathman SJ, Laubscher KH, Dar MM, Kirkwood JM. 2009. A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer. 115 4: 859–868.
   Google Scholar
• Ter-Minassian M, Wang Z, Asomaning K, Wu MC, Liu CY, Paulus JK, Liu G, Bradbury PA, Zhai R, Su L, Frauenhoffer CS, Hooshmand SM, De Vivo I, Lin X, Christiani DC, Kulke MH. 2011. Genetic associations with sporadic neuroendocrine tumor risk. Carcinogenesis. 32 8: 1216–1222.
   PubMed Web of Science ®Google Scholar
• Trinchieri G. 1998. Interleukin-12: A cytokine at the interface of inflammation and immunity. Adv Immunol. 70:83–243.
   PubMed Web of Science ®Google Scholar
• Veltri S, Smith JW2nd.. 1996. Interleukin 1 trials in cancer patients: A review of the toxicity, antitumor and hematopoietic effects. Stem Cells. 14 2: 164–176.
   Google Scholar
• Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. 1995. Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst. 87 8: 581–586.
   PubMed Web of Science ®Google Scholar
• Wadler S, Levy D, Frederickson HL, Falkson CI, Wang Y, Weller E, Burk R, Ho G, Kadish AS, Eastern Cooperative Oncology Group. 2004. A phase II trial of interleukin-12 in patients with advanced cervical cancer: Clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96. Gynecol Oncol. 92 3: 957–964.
   PubMed Web of Science ®Google Scholar
• Waldmann TA. 2006. The biology of interleukin-2 and interleukin-15: Implications for cancer therapy and vaccine design. Nat Rev Immunol. 6:595–601.
   PubMed Web of Science ®Google Scholar
• Wang KS, Frank DA, Ritz J. 2000. Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. Blood. 95 10: 3183–3190.
   Google Scholar
• Wang SS, Cerhan JR, Hartge P, Davis S, Cozen W, Severson RK, Chatterjee N, Yeager M, Chanock SJ, Rothman N. 2006. Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res. 66 19: 9771–9780.
   Google Scholar
• Watkins SK, Egilmez NK, Suttles J, Stout RD. 2007. IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J Immunol. 178 3: 1357–1362.
   PubMed Web of Science ®Google Scholar
• Watkins SK, Li B, Richardson KS, Head K, Egilmez NK, Zeng Q, Suttles J, Stout RD. 2009. Rapid release of cytoplasmic IL-15 from tumor-associated macrophages is an initial and critical event in IL-12-initiated tumor regression. Eur J Immunol. 39 8: 2126–2135.
   Web of Science ®Google Scholar
• Weiss GR, O'Donnell MA, Loughlin K, Zonno K, Laiberte RJ, Sherman ML. 2003. Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder. J Immunother. 26:343–348.
   PubMed Web of Science ®Google Scholar
• Wei YS, Lan Y, Luo B, Lu D, Nong HB. 2009. Association of variants in the interleukin-27 and interleukin-12 gene with nasopharyngeal carcinoma. Mol Carcinog. 48 8: 751–757.
   Google Scholar
• Xin Z, Sriram S. 1998. Vasoactive intestinal peptide inhibits IL-12 and nitric oxide production in murine macrophages. J Neuroimmunol. 89 1-2: 206–212.
   Google Scholar
• Yanagida T, Kato T, Igarashi O, Inoue T, Nariuchi H. 1994. Second signal activity of IL-12 on the proliferation and IL-2R expression of T helper cell-1 clone. J Immunol. 152 10: 4919–4928.
   Google Scholar
• Ye ZB, Ma T, Li H, Jin XL, Xu HM. 2007. Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma. World J Gastroenterol. 13 11: 1747–1751.
   Google Scholar
• Yoshimoto T, Takeda K, Tanaka T, Ohkusu K, Kashiwamura S, Okamura H, Akira S, Nakanishi K. 1998. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: Synergism with IL-18 for IFN-gamma production. J Immunol. 161 7: 3400–3407.
   Google Scholar
• Younes A, Pro B, Robertson MJ, Flinn IW, Romaguera JE, Hagemeister F, Dang NH, Fiumara P, Loyer EM, Cabanillas FF, McLaughlin PW, Rodriguez MA, Samaniego F. 2004. Phase II clinical trial of interleukin-12 in patients with relapsed and refractory non-Hodgkin's lymphoma and Hodgkin's disease. Clin Cancer Res. 10 16: 5432–5438.
   Google Scholar
• Yu MC, Yuan JM. 2004. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology. 127:S72–S78.
   PubMed Web of Science ®Google Scholar
• Yuzhalin A. 2011. The role of interleukin DNA polymorphisms in gastric cancer. Hum Immunol.. 72 11: 1128–1136.
   Google Scholar
• Zhao B, Meng LQ, Huang HN, Pan Y, Xu QQ. 2009. A novel functional polymorphism, 16974 A/C, in the interleukin-12-3' untranslated region is associated with risk of glioma. DNA Cell Biol. 28 7: 335–341.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Michelle Luo T, Jobin C, Young HA. 2011. Gut microbiota and probiotics in colon tumorigenesis. Cancer Lett. 309 2: 119–127.
   PubMed Web of Science ®Google Scholar
• van-Netten JP, Ashmead BJ, Parker RL, Thornton IG, Fletcher C, Cavers D, Coy P, Brigden ML. 1993. Macrophage-tumor cell associations: A factor in metastasis of breast cancer?. J Leukoc Biol. 54:360–362.
   Google Scholar